<DOC>
	<DOCNO>NCT01124786</DOCNO>
	<brief_summary>The purpose study determine whether CO-1.01 safe effective treatment patient metastatic pancreatic cancer low hENT1 expression compare gemcitabine .</brief_summary>
	<brief_title>A Study Comparing CO-1.01 With Gemcitabine First Line Therapy Patients With Metastatic Pancreatic Adenocarcinoma ( LEAP )</brief_title>
	<detailed_description>Pancreatic cancer serious form cancer . The majority patient present unresectable disease , condition often diagnose cancer relatively advance . The standard first-line treatment patient unresectable pancreatic cancer gemcitabine monotherapy . Unfortunately many patient fail derive benefit treatment . No clinical molecular marker establish predict benefit gemcitabine therapy , patient treat empirically evidence disease progression worsen performance status . The potential human equilibrative nucleoside transporter-1 ( hENT1 ) expression predict survival gemcitabine-treated patient study , data suggest patient low level tumor cell hENT1 expression derive less benefit gemcitabine treatment patient high level tumor cell hENT1 expression . These data support hypothesis test study patient pancreatic tumor express low level hENT1 derive minimal benefit gemcitabine , receive benefit CO-1.01 ( gemcitabine elaidate ) enter tumor cell hENT1-independent fashion .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Metastatic pancreatic ductal adenocarcinoma ( i.e. , Stage 4 ) . Histological/cytological confirmation metastatic tissue ( primary tumor ) central pathology laboratory ( H &amp; E stain ) ensure sufficient material available later hENT1 analysis . Adjuvant chemotherapy/radiotherapy ≥ 6 month prior randomization . Palliative radiotherapy ( administer ) ≥ 1 month prior randomization . CT scan ≤30 day prior randomization Performance Status ( ECOG ) 0 1 . Estimated life expectancy ≥ 12 week . Age ≥ 18 year . Adequate hematological biological function . Written consent Institutional Review Board/Institutional Ethics Committeeapproved Informed Consent Form prior studyspecific evaluation . Prior palliative chemotherapy pancreatic cancer . Radical pancreatic resection ( e.g. , Whipple procedure ) allow &lt; 6 month prior randomization . Exploratory laparotomy , palliative ( e.g. , bypass ) surgery , procedure ( e.g. , stent ) allow &lt; 14 day prior randomization . In case patient must sufficiently recover stable . Symptomatic brain metastasis . Participation investigational drug clinical study ≤ 30 day prior randomization . Concomitant treatment prohibit medication . History allergy gemcitabine egg . Presence serious unstable concomitant systemic disorder incompatible clinical study ( e.g. , substance abuse , uncontrolled intercurrent illness include active infection , arterial thrombosis , symptomatic pulmonary embolism ) . Any disorder would hamper protocol compliance . Prior nonpancreatic malignancy treat chemotherapy . Prior malignancy treat surgery radiotherapy alone must remission ≥ 3 year . The following prior malignancy allowable irrespective occur : situ carcinoma cervix , situ ductal breast cancer , lowgrade local bladder cancer , nonmelanotic skin cancer . Females pregnant breastfeeding . Refusal use adequate contraception fertile patient ( female male study 6 month last study treatment ) . Adequate form contraception doublebarrier method ( condom diaphragm spermicidal jelly foam ) ; oral , depot , injectable contraceptive ; intrauterine device ; tubal ligation . Any reason investigator considers patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>pancreatic</keyword>
	<keyword>pancreas</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>human equilibrative nucleoside transporter-1 ( hENT1 )</keyword>
	<keyword>CO-1.01</keyword>
	<keyword>CO-101</keyword>
	<keyword>CO101</keyword>
	<keyword>Stage 4</keyword>
	<keyword>Stage IV</keyword>
</DOC>